Is Rohto Pharmaceutical profitable in 2026?

Yes. Rohto reported record consolidated sales of approximately ¥343.7 billion for the fiscal year ended March 2026, up roughly 11-14% year over year, per its own financial results released May 13, 2026, driven by growth in Asia and Europe.

Who owns Rohto Pharmaceutical?

Rohto is publicly traded on the Tokyo Stock Exchange Prime Market under ticker 4527, with a market cap of about ¥531 billion as of July 2026. Kunio Yamada, a fourth-generation family member, serves as Chairman; largest disclosed institutional holder is MFS International UK at 5.21% as of July 2026.

Could AI replace Rohto Pharmaceutical?

Unlikely soon. Rohto is a licensed OTC pharmaceutical manufacturer since 1899 whose Hada Labo and Melano CC brands are the number one and two basic-skincare brands in Japanese drugstores per company data from May 2025, protected by manufacturing licensure and retail distribution AI cannot replicate.

Who is Rohto Pharmaceutical's biggest competitor?

Rohto competes with Kao (Bio«, Curél), Shiseido, KOSÉ, Kobayashi Pharmaceutical, and Pola Orbis in Japanese skincare and OTC. As of 2026 none of these rivals has dislodged Hada Labo or Melano CC from their top drugstore shelf positions.

Why is an activist investor targeting Rohto Pharmaceutical?

London-based Asset Value Investors, holding about 1.89% of shares, launched its 'Awakening Rohto' campaign in April 2025 and by May 2026 sought to remove Chairman Kunio Yamada at the June 2026 AGM, citing losses in an unprofitable regenerative-medicine unit and the Eu Yan Sang acquisition.

Did Rohto Pharmaceutical acquire the Obagi skincare brand?

Yes. Rohto acquired outright ownership of the Obagi trademark in Japan from Waldencast plc for $82.5 million in November 2025, ending a licensing arrangement that had lasted over two decades.

Consumer brands · Japan

Rohto Pharmaceutical Co., Ltd.

rohto.co.jp ↗

127-year-old Japanese OTC pharma maker behind Hada Labo and Melano CC skincare.

Hard to displace

Assessed 25 July 2026 · Evidence as of 25 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 25 July 2026 · Checkable from June 2026 · Every call on the record Checkpoint: AGM shareholder vote on Asset Value Investors' proposal to remove Chairman Kunio Yamada

The call

Rohto's drugstore brands and manufacturing base look secure, while the real pressure sits in a shareholder fight over capital allocation, not AI or product substitution.

Rohto Pharmaceutical makes over-the-counter skincare products sold in drugstores, with top brands like Hada Labo and Melano CC making up more than half its sales. It is hard to replace because it holds government licenses to manufacture pharmaceuticals, has long-standing relationships with retailers, owns secret formulas competitors cannot easily recreate, and customers trust its brands, which AI companies cannot suddenly copy. The key question is whether activist investors convince the company to sell off money-losing divisions and return more cash to shareholders in 2026, which would determine whether the stock price keeps up with the rest of the market or falls behind.

Why

AI pressure: AI skin/eye diagnostic tools from KOSE and Shiseido. Rivals now ship AI diagnostic tools that copy Rohto's marketing gimmick, weakening its point of difference at the shelf. Could AI do the core job? Unlikely.

Bigger players: Shiseido and KOSE. Larger Japanese cosmetics groups compete directly for the same drugstore shelf space with their own skincare lines. Could a giant copy it? Probably.

What protects it. Pharmaceutical manufacturing licenses, decades of drugstore distribution, and #1/#2 brand recognition for Hada Labo and Melano CC.

What would change this call

Outcome of June 2026 AGM vote on AVI's proposal to remove Chairman Kunio Yamada. Shows whether activists gain control over capital allocation and strategic direction.
Whether Rohto divests or restructures its regenerative-medicine unit within FY3/27. Would confirm activist pressure is reshaping business focus, not just governance noise.
Profitability trend of Eu Yan Sang and Obagi Japan units in FY3/27 earnings reports. Would show whether M&A integration is dragging on core P&L as AVI alleges.

Key numbers

FY3/26 consolidated sales hit record ¥343.7B (2026-05-13)
FY3/25 sales ¥308,625M, up 14.0% YoY (2025-05-13)
Skincare now over 50% of group revenue (2026-05)

Named risks

Activist Asset Value Investors seeks to remove Chairman Kunio Yamada at June 2026 AGM. Severity: high
Integration drag from Eu Yan Sang (2024) and Obagi Japan (2025) acquisitions on core profitability. Severity: medium
Shareholder returns have underperformed the TOPIX index over the five years to 2026 per AVI. Severity: medium
Continued investment in unprofitable regenerative-medicine unit cited by activists as capital misallocation. Severity: medium
Generic AI skin-diagnostic tools from rivals could commoditize Rohto's event-based marketing differentiator. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Shiseido	contesting	Adjacent skincare giant but has not displaced Hada Labo or Melano CC from top drugstore slots as of 2026
Kao Corporation	contesting	Bio« and Curél compete directly in Japanese drugstore skincare, no shelf displacement reported as of 2026
KOSÉ Corporation	contesting	Prestige skincare rival with roughly ¥329 billion revenue per 2026 comparison
Kobayashi Pharmaceutical	contesting	OTC and quasi-drug competitor in same Japanese regulatory category as of 2026
Pola Orbis Holdings	contesting	Prestige anti-aging peer with about ¥170 billion revenue per 2026 data

Questions people ask

Is Rohto Pharmaceutical profitable in 2026?: Yes. Rohto reported record consolidated sales of approximately ¥343.7 billion for the fiscal year ended March 2026, up roughly 11-14% year over year, per its own financial results released May 13, 2026, driven by growth in Asia and Europe.
Who owns Rohto Pharmaceutical?: Rohto is publicly traded on the Tokyo Stock Exchange Prime Market under ticker 4527, with a market cap of about ¥531 billion as of July 2026. Kunio Yamada, a fourth-generation family member, serves as Chairman; largest disclosed institutional holder is MFS International UK at 5.21% as of July 2026.
Could AI replace Rohto Pharmaceutical?: Unlikely soon. Rohto is a licensed OTC pharmaceutical manufacturer since 1899 whose Hada Labo and Melano CC brands are the number one and two basic-skincare brands in Japanese drugstores per company data from May 2025, protected by manufacturing licensure and retail distribution AI cannot replicate.
Who is Rohto Pharmaceutical's biggest competitor?: Rohto competes with Kao (Bio«, Curél), Shiseido, KOSÉ, Kobayashi Pharmaceutical, and Pola Orbis in Japanese skincare and OTC. As of 2026 none of these rivals has dislodged Hada Labo or Melano CC from their top drugstore shelf positions.
Why is an activist investor targeting Rohto Pharmaceutical?: London-based Asset Value Investors, holding about 1.89% of shares, launched its 'Awakening Rohto' campaign in April 2025 and by May 2026 sought to remove Chairman Kunio Yamada at the June 2026 AGM, citing losses in an unprofitable regenerative-medicine unit and the Eu Yan Sang acquisition.
Did Rohto Pharmaceutical acquire the Obagi skincare brand?: Yes. Rohto acquired outright ownership of the Obagi trademark in Japan from Waldencast plc for $82.5 million in November 2025, ending a licensing arrangement that had lasted over two decades.

Timeline

2026-07-14Rohto and E-Derm sign exclusive evaluation and licensing option agreement for hair-tech
2026-05-13FY3/26 results show record consolidated sales of about ¥343.7 billion
2026-05-05Asset Value Investors escalates push to remove Chairman Kunio Yamada at June 2026 AGM
2026-04-13Rohto and Tokyo Women's Medical University build next-gen vascularized artificial skin model
2026-04-12Rohto reports AI eye-age imaging data from over 140,000 Osaka-Kansai Expo visitors
2025-12-15Rohto abolishes document screening, adopts 15-minute Entry Meet hiring format from Jan 2026
2025-11-26Rohto buys Obagi trademark rights in Japan from Waldencast for $82.5 million
2025-10-06RealLab AI, co-developed with Futsupa, wins CEATEC AWARD 2025 Next Generation category
2025-06Hidetoshi Segi becomes President, succeeding Masashi Sugimoto
2025-05-13FY3/25 results show consolidated net sales of ¥308,625 million, up 14.0% YoY

Head to head

Kao Corporation vs Rohto Pharmaceutical Co., Ltd.

Revision history

25 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Hermes International Compagnie Financiere Richemont Inditex (Zara)